Pulse Biosciences, Inc. (PLSE) Financial Ratios
12 years of historical data (2014–2025) · Healthcare · Medical - Instruments & Supplies
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
16.37
↑+45% vs avg
5yr avg: 11.30
30Y Low2.8·High24.2
ROE
↑
-74.4%
↓+59% vs avg
5yr avg: -181.9%
30Y Low-350%·High-3%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
PLSE Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Pulse Biosciences, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $1.3B | $925M | $1.0B | $588M | $94M | $414M | $555M | $278M | $196M | $348M | $72M |
| Enterprise Value | $1.3B | $852M | $908M | $553M | $109M | $397M | $554M | $278M | $145M | $345M | $69M |
| P/E Ratio → | -18.14 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 3818.65 | 2643.82 | — | — | 134.29 | 292.06 | — | — | — | — | — |
| P/B Ratio | 16.37 | 11.47 | 8.85 | 13.25 | — | 11.60 | 24.23 | 9.05 | 2.95 | 7.57 | 2.83 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
PLSE EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 2434.67 | — | — | 155.45 | 279.82 | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
PLSE Profitability
Margins and return-on-capital ratios measuring operating efficiency
Pulse Biosciences, Inc. earns an operating margin of -21982.6%. A negative ROE of -74.4% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | -360.0% | -360.0% | — | — | -1606.3% | -38.8% | — | — | — | — | — |
| Operating Margin | -21982.6% | -21982.6% | — | — | -8293.9% | -4443.9% | — | — | — | — | — |
| Net Profit Margin | -20794.6% | -20794.6% | — | — | -8357.9% | -4489.4% | — | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -74.4% | -74.4% | -67.3% | -200.5% | -349.9% | -217.3% | -185.5% | -94.8% | -66.8% | -71.7% | -48.9% |
| ROA | -63.7% | -63.7% | -55.9% | -61.6% | -88.6% | -133.3% | -119.5% | -81.7% | -62.3% | -67.2% | -46.8% |
| ROIC | -876.1% | -876.1% | -567.8% | -301.1% | -281.9% | -235.6% | -143.2% | -157.1% | -98.5% | -58.8% | -43.2% |
| ROCE | -73.1% | -73.1% | -64.3% | -70.1% | -98.7% | -158.6% | -140.4% | -91.4% | -65.9% | -70.8% | -49.2% |
PLSE Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $81M exceeds total debt of $8M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.09 | 0.09 | 0.08 | 0.21 | — | 0.32 | 0.50 | 0.22 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.91 | -0.95 | -0.79 | — | -0.49 | -0.05 | -0.01 | -0.77 | -0.07 | -0.08 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | -39.61 | — | — | — | — | — | — | — |
Net cash position: cash ($81M) exceeds total debt ($8M)
PLSE Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Pulse Biosciences, Inc.'s current ratio of 10.53x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 6.76x to 10.53x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 10.53 | 10.53 | 11.88 | 6.76 | 10.39 | 4.30 | 2.95 | 5.92 | 19.42 | 17.39 | 16.40 |
| Quick Ratio | 10.51 | 10.51 | 11.88 | 6.76 | 10.39 | 3.62 | 2.95 | 5.92 | 19.42 | 17.39 | 16.40 |
| Cash Ratio | 10.19 | 10.19 | 11.74 | 6.61 | 10.22 | 3.36 | 2.70 | 5.70 | 19.17 | 17.20 | 16.14 |
| Asset Turnover | — | 0.00 | — | — | 0.01 | 0.03 | — | — | — | — | — |
| Inventory Turnover | 11.84 | 11.84 | — | — | — | 0.34 | — | — | — | — | — |
| Days Sales Outstanding | — | 285.74 | — | — | — | 15.70 | — | — | — | — | — |
PLSE Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Pulse Biosciences, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $67M | $58M | $48M | $34M | $28M | $23M | $21M | $17M | $15M | $11M |
Peer Comparison
Compare PLSE with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 PLSEYou | $1B | -18.1 | — | — | -360.0% | -21982.6% | -74.4% | -876.1% | — |
 INVA | $2B | 6.9 | 8.1 | 9.9 | 72.3% | 38.5% | 29.1% | 14.2% | 1.3 |
 NVCR | $2B | -13.8 | — | — | 74.5% | -23.5% | -38.9% | -16.4% | — |
 ATEC | $1B | -8.1 | 3752.1 | 422.6 | 69.6% | -10.7% | -630.7% | -12.6% | 1425.2 |
 ANAB | $3B | -145.6 | 52.9 | 147.2 | 99.0% | 20.4% | -24.5% | 55.1% | 0.3 |
 INMD | $882M | 9.7 | 6.9 | 10.5 | 78.5% | 23.0% | 13.5% | 13.5% | 0.2 |
 MDT | $100B | 21.6 | 14.3 | 19.3 | 65.3% | 17.8% | 9.4% | 6.0% | 3.2 |
 BSX | $84B | 29.2 | 25.3 | 23.0 | 69.0% | 19.8% | 12.4% | 8.8% | 3.3 |
 ABT | $151B | 11.4 | 15.8 | 23.8 | 50.8% | 16.3% | 30.9% | 9.9% | 1.5 |
 SYK | $113B | 35.0 | 20.3 | 26.3 | 64.0% | 19.5% | 15.1% | 11.4% | 2.4 |
 ISRG | $161B | 57.6 | 43.6 | 64.7 | 66.0% | 29.3% | 16.6% | 15.0% | 0.1 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 12 years · Updated daily
See PLSE's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs PLSE Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare PLSE vs INVA
Side-by-side business, growth, and profitability comparison vs Innoviva, Inc..
Start ComparisonPLSE — Frequently Asked Questions
Quick answers to the most common questions about buying PLSE stock.
What is Pulse Biosciences, Inc.'s P/E ratio?
Pulse Biosciences, Inc.'s current P/E ratio is -18.1x. This places it at the 50th percentile of its historical range.
What is Pulse Biosciences, Inc.'s ROE?
Pulse Biosciences, Inc.'s return on equity (ROE) is -74.4%. The historical average is -116.6%.
Is PLSE stock overvalued?
Based on historical data, Pulse Biosciences, Inc. is trading at a P/E of -18.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Pulse Biosciences, Inc.'s profit margins?
Pulse Biosciences, Inc. has -360.0% gross margin and -21982.6% operating margin.